Design Therapeutics DSGN 深 沪
已收盘 08-28 16:00:00 美东时间
15.11
-0.140
-0.92%
华盛通- 最 高15.36
- 今 开15.12
- 成交量 82.08万股
- 最 低 14.80
- 昨 收 15.25
- 总市值 9.46亿
- 52周最高 17.25
- 市盈率 静 --
- 换手率 1.31%
- 52周最低 5.28
- 委 比 -19.03%
- 总股本 6258.17万
- 历史最高 50.50
- 量 比 1.53
- 振 幅 3.67%
- 历史最低 1.94
- 每 手 1
- 风险率 2.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were mostly lower this morning, with the Nasdaq 100 futures falling around 0.3% on Friday. Shares of Marvell Technology Inc (NASDAQ:MRVL) fell sharply in pre-market trading following financial results for the second quarter. Marvell posted second-quarter revenue of $2.74 billion, ...
08-28 20:02
Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) Estimate
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate of $(0.34) by 5.88 percent. This is a 5.88 percent increase over losses of $(0.34) per share from the same period last year.
08-03 20:04
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
Design Therapeutics reported Q2 2026 financial results and business updates. Positive four-week data from the RESTORE-FA trial for DT-216P2 in Friedreich ataxia supported modifications to the trial, with 12-week data expected in Q1 2027. Patient dosing began for DT-818 in myotonic dystrophy type 1. Cash and securities of $207.4 million provide strong financial runway. R&D expenses were $16.4 million, G&A expenses $5.8 million, and net loss $20.2 ...
08-03 12:00
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
Nvidia (NVDA) and Lam Research (LRCX) are among the largest names on Oppenheimer’s latest “best of the best” momentum screen. Oppenheimer’s technical analysis team said the list provides technical col...
07-20 03:10
Design Therapeutics Starts Patient Dosing In Its Phase 1 Multiple-Ascending Dose Clinical Study Of DT-818 In Adults With Myotonic Dystrophy Type-1
Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the initiation of patient dosing in its Phase 1 multiple-ascending dose (MAD) clinical trial evaluating DT-818 in adults with myotonic dys...
06-30 20:06
Design Therapeutics Announces Initiation of Patient Dosing in Phase 1 Multiple Ascending Dose Trial of DT-818 for Myotonic Dystrophy Type-1
Design Therapeutics has initiated a Phase 1 clinical trial for DT-818, a GeneTAC® molecule targeting myotonic dystrophy type-1 (DM1) by reducing transcription of the mutant DMPK allele. The trial aims to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with DM1. DT-818 has shown promise in preclinical studies, potentially addressing the underlying genetic cause of DM1. The company anticipates reporting data in 2027. D...
06-30 12:00
Design Therapeutics shares are trading lower. The company announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia.
Design Therapeutics shares are trading lower. The company announced biomarker a...
05-18 22:42
Design Therapeutics reports positive Phase 1/2 DT-216P2 data
Design Therapeutics ( ($DSGN) ) has issued an update. On May 18, 2026, Design T...
05-18 19:53
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also decline in pre-market trading.
05-11 20:02
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
